Brazil's local vaccine production aims for autonomy
Brazil’s public sector scientific and technological capacity is facing the challenges of vaccine diplomacy
You must be signed in to read this analysis
In this article
- AstraZeneca's agreement with Fiocruz
- Sinovac's agreement with Butantan
- Political problems
What is this?
This article is from the Oxford Analytica Daily Brief, which analyses geopolitical, economic, social, business and industrial developments on a global and regional basis, providing clients with timely, authoritative analysis every business day of the year. Find out more about the Oxford Analytica Daily Brief, or request a trial.
